Product Details
FAB
- Comprehensive validation - Validated with various antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human BAFF / BAFFR Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human BAFF binding to BAFFR within one hour. It can also be used as a universal detection tool to identify the ability of human BAFF to bind to human BAFFR.
Storage
1. Store the unopened kit at 2-8°C upon receipt.
2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.
3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRTP036-C01Human BAFFR Protein Europium-chelate100 tests/500 testsFRTP036-C02FA Labeled Human BAFF Protein100 tests/500 testsFRTP036-C03Anti-BAFF Neutralizing Antibody30 μg/100 tests
150 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human BAFF / BAFFR Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human BAFFR and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human BAFF Protein as the Acceptor.
— When the sample does not contain the inhibitors that block the binding of human BAFF to human BAFFR, the Donor and Acceptor are in close proximity because of the binding of human BAFF and human BAFFR. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).
— When the sample contains the inhibitors that block the binding of human BAFF to human BAFFR, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.

ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.

In this TR-FRET assay, Human BAFFR Protein Europium-chelate is used as the Donor and FA Labeled Human BAFF Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human BAFFR and human BAFF using Anti-BAFF Neutralizing Antibody resulting in a typical IC50 of 0.4001 nM (QC tested).

In this TR-FRET assay, Human BAFFR Protein Europium-chelate is used as the Donor and FA Labeled Human BAFF Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human BAFFR and human BAFF using Anti-BAFF Neutralizing Antibody resulting in a typical IC50 of 0.4001 nM (QC tested).
Customer Reviews Writing Reviews

Recent Advances
- English Name:
B-cell-activating factor/B lymphocyte stimulator
- Category:
- Approved Drugs:
2 Details
- Drugs in Clinical Trials:
8 Details
- Highest Development Stage:
Approved



















